These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 31203927

  • 1. Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice.
    Sharif K, Gendelman O, Langevitz P, Reitblat T, Watad A, Shoenfeld Y, Azuri J, Amital H, Bragazzi NL, Shovman O.
    Best Pract Res Clin Rheumatol; 2018 Oct; 32(5):692-700. PubMed ID: 31203927
    [Abstract] [Full Text] [Related]

  • 2. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Canhão H, McInnes IB, Ribeiro RM, Fonseca JE.
    Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
    [Abstract] [Full Text] [Related]

  • 3. The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes.
    De Marco G, Helliwell P, McGonagle D, Emery P, Coates LC, Hensor EMA, Marzo-Ortega H.
    BMC Musculoskelet Disord; 2017 Jul 18; 18(1):303. PubMed ID: 28720139
    [Abstract] [Full Text] [Related]

  • 4. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.
    Ann Rheum Dis; 2019 May 18; 78(5):610-616. PubMed ID: 30808625
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
    Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A.
    Ann Rheum Dis; 2014 Sep 18; 73(9):1689-94. PubMed ID: 24748630
    [Abstract] [Full Text] [Related]

  • 6. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2014 Jan 18; 73(1):132-7. PubMed ID: 23291385
    [Abstract] [Full Text] [Related]

  • 7. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž, Tomšič M, Praprotnik S, Slovenian Rheumatologists.
    Clin Rheumatol; 2019 Feb 18; 38(2):297-305. PubMed ID: 30324406
    [Abstract] [Full Text] [Related]

  • 8. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.
    Arthritis Res Ther; 2019 Sep 14; 21(1):208. PubMed ID: 31521192
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 14; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 10. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B, Sexton J, Wierød A, Bakland G, Rødevand E, Krøll F, Kvien TK.
    Semin Arthritis Rheum; 2020 Feb 14; 50(1):12-16. PubMed ID: 31358361
    [Abstract] [Full Text] [Related]

  • 11. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep 14; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 12. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V, Plosker GL.
    BioDrugs; 2009 Sep 14; 23(2):125-35. PubMed ID: 19489653
    [Abstract] [Full Text] [Related]

  • 13. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.
    Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B.
    Rheumatology (Oxford); 2015 May 14; 54(5):915-26. PubMed ID: 25349441
    [Abstract] [Full Text] [Related]

  • 14. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K.
    Mod Rheumatol; 2016 May 14; 26(1):24-8. PubMed ID: 26140464
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr 14; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 16. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A.
    Ann Rheum Dis; 2015 Mar 14; 74(3):538-46. PubMed ID: 24344160
    [Abstract] [Full Text] [Related]

  • 17. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D'Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G.
    Semin Arthritis Rheum; 2017 Aug 14; 47(1):108-114. PubMed ID: 28216195
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
    Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A.
    Ann Rheum Dis; 2013 Nov 14; 72(11):1777-85. PubMed ID: 23161902
    [Abstract] [Full Text] [Related]

  • 19. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.
    Arthritis Rheum; 2009 Apr 14; 60(4):976-86. PubMed ID: 19333944
    [Abstract] [Full Text] [Related]

  • 20. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb 14; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.